Plasma vitamin D levels and vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer

Liu, Yao; Chen, Wei; Hu, Zhibin; Xu, Lin; Shu, Yongqian; Pan, Shiyang; Dai, Juncheng; Jin, Guangfu; Ma, Hongxia; Shen, Hongbing

doi:10.1007/s11670-011-0033-3

Cited by 32 publications

(33 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a US study of 447 early stage non-small cell lung cancer patients also observed longer survival for those with higher serum 25(OH)D at diagnosis, however the association was not statistically significant (10). In contrast, higher serum 25(OH)D at diagnosis was associated with shorter survival time in a Chinese study of 87 non-small cell lung cancer cases (12). No association between serum 25(OH)D and survival was observed for 294 patients with advanced stage non-small cell carcinoma (11), suggesting that vitamin D may be less protective for later stage, more aggressive lung tumors.…”

Section: Discussionmentioning

confidence: 92%

“…Two studies observed better survival among lung cancer cases with higher circulating 25(OH)D measured shortly after diagnosis (9, 10), but other studies observed that higher 25(OH)D concentration at diagnosis was not association with survival (11) or associated with worse survival (12). To our knowledge no other studies have examined pre-diagnostic serum 25(OH)D in relation to survival among lung cancer cases.…”

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Serum vitamin D, vitamin D binding protein, and lung cancer survival

et al. 2014

View full text Add to dashboard Cite

Objectives Vitamin D may prolong cancer survival by inhibiting tumor progression and metastasis, however, there are limited epidemiologic studies regarding the association between circulating 25-hydroxyvitamin D (25(OH)D) and lung cancer survival. The aim of this study was to examine the relationship between serum 25(OH)D and lung cancer specific survival and to evaluate whether vitamin D binding protein (DBP) concentration modified this association. Materials and Methods 25(OH)D and DBP were measured in fasting serum samples from 500 male lung cancer cases in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cox proportional hazards regression was used to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for lung cancer related death according to quartiles of season-specific 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, a proxy for free circulating 25(OH)D. Results Comparing highest to lowest quartiles, serum 25(OH)D (HR=1.18; 95% CI: 0.89–1.56) and DBP (HR=0.95; 95% CI: 0.71–1.26) were not associated with lung cancer survival and DBP concentration did not modify the association with 25(OH)D (p for interaction=0.56). There was suggestion of an association between higher serum 25(OH)D and better survival from adenocarcinoma (HR=0.64; 95% CI: 0.17–2.45) and small cell carcinoma (HR=0.55; 95% CI: 0.21–1.45), but these estimates were based on a relatively small number of cases. Conclusion Serum 25(OH)D was not associated with overall lung cancer survival regardless of DBP concentration, however, these findings should be examined in other studies that include women and subjects with higher 25(OH)D levels.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Introductionmentioning

confidence: 98%

Serum vitamin D, vitamin D binding protein, and lung cancer survival

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The VDR TaqI and BsmI variants have been associated with survival in non-small cell lung cancer patients (105), and an international multicenter case-control study consortium (the Genes, Environment, and Melanoma (GEM) Study) found significant associations with melanoma mortality for 8 common VDR variants (106) ( Table 2). Mortality was also associated with the vitamin D binding protein gene, GC, and RXRA in the Nurses' Health Study and Health Professionals Followup Study (107) ( Table 2).…”

Section: Vitamin D-related Genesmentioning

confidence: 99%

Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges

Mondul

Weinstein

Layne

et al. 2017

Epidemiologic Reviews

167

133

View full text Add to dashboard Cite

There has been substantial enthusiasm recently regarding the potential role of vitamin D in the primary and secondary prevention of cancer. Laboratory studies demonstrate a range of anticarcinogenic effects for vitamin D compounds, but human studies have yielded little consistent evidence supporting a protective association. Higher circulating levels of vitamin D (i.e., 25-hydroxyvitamin D or 25(OH)D) appear to be associated with reduced risk of colorectal and bladder malignancies, but higher risk of prostate and possibly pancreatic cancers, with no clear association for most other organ sites examined. Despite there being no official institutional recommendations regarding the use of vitamin D supplements for cancer prevention, screenings for vitamin D deficiency and vitamin D supplement use have increased substantially over the past decade. These widespread practices demonstrate that population sociobehavioral changes are often adopted before scientifically well-informed policies and recommendations are available. This review critically examines the currently available epidemiologic literature regarding the associations between circulating 25(OH)D, vitamin D supplementation, and vitamin D-related genetic variation and cancer risk and mortality, with a particular emphasis on prospective studies. We identify several important gaps in our scientific knowledge that should be addressed in order to provide sufficient reproducible data to inform evidence-based recommendations related to optimal 25(OH)D concentrations (and any role for vitamin D supplementation) for the primary and secondary prevention of cancer. With few exceptions, such recommendations cannot be made at this time.

show abstract

“…The vitamin D-binding protein (encoded by the group-specific component , GC gene) mainly promotes transportation of vitamin D metabolites [11]. Laboratory studies showed that high 1,25(OH) 2 D levels can inhibit differentiation and proliferation in human lung cancer cell lines [12], and circulating 25(OH)D level may predict early-stage NSCLC patients’ survival [13,14]. Vitamin D-related genes have highly polymorphic genotypes in different human populations.…”

Section: Introductionmentioning

confidence: 99%

Vitamin D-Related Gene Polymorphisms, Plasma 25-Hydroxy-Vitamin D, Cigarette Smoke and Non-Small Cell Lung Cancer (NSCLC) Risk

Cheng

Yang

2016

IJMS

View full text Add to dashboard Cite

Epidemiological studies regarding the relationship between vitamin D, genetic polymorphisms in the vitamin D metabolism, cigarette smoke and non-small cell lung cancer (NSCLC) risk have not been investigated comprehensively. To search for additional evidence, the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique and radioimmunoassay method were utilized to evaluate 5 single-nucleotide polymorphisms (SNPs) in vitamin D receptor (VDR), 6 SNPs in 24-hydroxylase (CYP24A1), 2 SNPs in 1α-hydroxylase (CYP27B1) and 2 SNPs in vitamin D-binding protein (group-specific component, GC) and plasma vitamin D levels in 426 NSCLC cases and 445 controls from China. Exposure to cigarette smoke was ascertained through questionnaire information. Multivariable linear regressions and mixed effects models were used in statistical analysis. The results showed that Reference SNP rs6068816 in CYP24A1, rs1544410 and rs731236 in VDR and rs7041 in GC were statistically significant in relation to reduction in NSCLC risk (p < 0.001–0.05). No significant connection was seen between NSCLC risk and overall plasma 25-hydroxyvitamin D [25(OH)D] concentrations, regardless of smoking status. However, the mutation genotype of CYP24A1 rs6068816 and VDR rs1544410 were also significantly associated with increased 25(OH)D levels only in both the smoker and non-smoker cases (p < 0.01–0.05). Meanwhile, smokers and non-smokers with mutated homozygous rs2181874 in CYP24A1 had significantly increased NSCLC risk (odds ratio (OR) = 2.14, 95% confidence interval (CI) 1.47–3.43; p = 0.031; OR = 3.57, 95% CI 2.66–4.74; p = 0.019, respectively). Smokers with mutated homozygous rs10735810 in VDR had significantly increased NSCLC risk (OR = 1.93, 95% CI 1.41–2.76; p = 0.015). However, smokers with mutated homozygous rs6068816 in CYP24A1 had significantly decreased NSCLC risk (OR = 0.43, 95% CI 0.27–1.02; p = 0.006); and smokers and non-smokers with mutated homozygous rs1544410 in VDR had significantly decreased NSCLC risk (OR = 0.51, 95% CI 0.34–1.17; p = 0.002; OR = 0.26, 95% CI 0.20–0.69; p = 0.001, respectively). There are significant joint effects between smoking and CYP24A1 rs2181874, CYP24A1 rs6068816, VDR rs10735810, and VDR rs1544410 (p < 0.01–0.05). Smokers with mutated homozygous rs10735810 in VDR had significantly increased NSCLC risk (OR = 1.93, 95% CI 1.41–2.76; p = 0.015). In summary, the results suggested that the lower the distribution of vitamin D concentration, the more the genetic variations in CYP24A1, VDR and GC genes may be associated with NSCLC risk. In addition, there are significant joint associations of cigarette smoking and vitamin D deficiency on NSCLC risk.

show abstract

Plasma vitamin D levels and vitamin D receptor polymorphisms are associated with survival of non-small cell lung cancer

Cited by 32 publications

References 22 publications

Serum vitamin D, vitamin D binding protein, and lung cancer survival

Serum vitamin D, vitamin D binding protein, and lung cancer survival

Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges

Vitamin D-Related Gene Polymorphisms, Plasma 25-Hydroxy-Vitamin D, Cigarette Smoke and Non-Small Cell Lung Cancer (NSCLC) Risk

Contact Info

Product

Resources

About